PeptideWell-studiedGrowth Hormone Secretagogue

Tesamorelin

GHRH analog (NOT a GLP-1 — safety differs)

Typical dose

1–2 mg

once daily · SubQ

Half-life

~26–38 minutes

What is Tesamorelin?

FDA-approved GHRH analogue (Egrifta). Specifically approved for visceral fat reduction in HIV lipodystrophy.

How Tesamorelin works

Binds pituitary GHRH receptors to stimulate GH secretion, with clinical evidence demonstrating preferential reduction of visceral (intra-abdominal) adipose tissue.

Benefits & uses

Visceral fat reduction
GH stimulation
Cognitive improvement
Muscle retention
Anti-aging
Reduces visceral (abdominal) fat
Raises IGF-1 / growth hormone
May improve body composition
Studied for HIV-associated lipodystrophy

Common uses: Visceral adipose reduction, body composition, GH deficiency, anti-aging.

Tesamorelin dosage

Typical dose: Typical: 1–2 mg once daily SubQ. 12+ weeks.
Protocol notes: 1-2mg per injection, daily.

Tesamorelin half-life

~26–38 minutes

Tesamorelin side effects

Injection site reactions, fluid retention, arthralgia. May elevate blood glucose.

Injection site pain, redness, or swelling
Fluid retention / peripheral edema
Joint pain (arthralgia)
Elevated blood glucose — monitor if pre-diabetic
Injection-site reactions
Joint pain/swelling
Fluid retention
Tingling/numbness (carpal-tunnel-like)
Raised blood sugar

Warnings & monitoring

Research use only outside FDA indication
Avoid in active cancer
Monitor IGF-1 levels
Can raise blood sugar / reduce insulin sensitivity — caution with diabetes
Not for active cancer (raises IGF-1)
Not for pregnancy
This is a GHRH analog, not a GLP-1 — different risk profile

Preparation & storage

Preparation: Mix a 10 mg vial with 2 mL bac water → 5 mg/mL. A 2 mg dose = 0.4 mL = 40 units.
Reconstitution: Reconstitute a 10 mg vial with 2 mL BAC water → 5 mg/mL. A 2 mg dose = 0.4 mL = 40 units on a U-100 syringe.
Storage: Refrigerate unreconstituted (2–8 °C). Reconstituted: refrigerate and use within 24 hours.

Tesamorelin interactions

with CJC-1295
Caution · mild
Tesamorelin and CJC-1295 are both GHRH analogs. Stacking offers no synergy; redundant receptor competition just doubles cost.
Timing: Choose one GHRH analog per protocol
with Ipamorelin
Compatible
Tesamorelin (FDA-approved GHRH analogue) and Ipamorelin work through GHRH and ghrelin receptor pathways respectively, providing GH amplification at different times of day.
Timing: Tesamorelin in the morning for visceral fat; Ipamorelin before bed for recovery and sleep
with Ipamorelin
Compatible
Tesamorelin's stabilized GHRH plus Ipamorelin's clean GHRP action is a low-side-effect alternative to CJC/Ipa.
Timing: Same injection or back-to-back; nightly fasted

Commonly stacked with

Ipamorelin CJC-1295 (no DAC)BPC-157 Retatrutide

Track Tesamorelin in Protokol.

Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.